emselex
pharmaand gmbh - bromhidrat de darifenacin - urinary incontinence, urge; urinary bladder, overactive - urologicals, medicamente pentru frecvenței urinare si incontinenta - tratamentul simptomatic al incontinenței de urgență și / sau frecvenței și urgenței urinare crescute, care pot apărea la pacienții adulți cu sindrom de vezică urinară hiperactivă.
emselex 15mg
novartis pharma gmbh - germania - darifenacinum - compr. cu elib. prel. - 15mg - urologice, med. pt. frecv. urinara crescuta si incontinenta
emselex 7,5mg
novartis pharma gmbh - germania - darifenacinum - compr. cu elib. prel. - 7,5mg - urologice, med. pt. frecv. urinara crescuta si incontinenta
orungal 100 mg
janssen-cilag spa - italia - itraconazolum - caps. - 100mg - antimicotice de uz sistemic derivati de triazol
tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - agenți antineoplazici - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.
digoxin grindeks 0,25 mg comprimate
grindeks sa - digoxinum - comprimate - 0,25 mg
hepcludex
gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirale pentru uz sistemic - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - agenți antineoplazici - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.
retsevmo
eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - agenți antineoplazici - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.
digoxin grindeks 0.25 mg comprimate
grindeks sa - digoxinum - comprimate - 0.25 mg